<DOC>
	<DOCNO>NCT02573467</DOCNO>
	<brief_summary>This extension study provide data evaluate efficacy , safety , tolerability three dos BYM338 ass long-term effect BYM338 patient sporadic inclusion body myositis . Patients complete core study qualify extension study enter Treatment Period 1 , continue study drug receive core study ( either one three BYM338 dos placebo ) . Treatment Period 1 continue dose BYM338 best benefit-risk profile determine select . The duration Treatment Period 1 could one year ( estimate 6 8 month ) total duration Treatment Period 1 depend upon time selection dose Treatment Period 2 . Once dose best benefit-risk profile select , ongoing subject ( include receive placebo ) enter Treatment Period 2 switch open-label treatment BYM338 select dose . Treatment Period 2 continue BYM338 approve commercially available country investigational site .</brief_summary>
	<brief_title>An Extension Study Efficacy , Safety Tolerability BYM338 ( Bimagrumab ) Patients With Sporadic Inclusion Body Myositis Who Previously Participated Core Study CBYM338B2203</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis , Inclusion Body</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<criteria>Patients complete core study Written inform consent must obtain extension study assessment perform . Able communicate well investigator . Willing participate entire duration extension study commitment follow study requirement procedure . Women pregnant Women childbearing potential unless use highly effective method contraception dose 6 month last BYM338 dose . Current use prohibit treatment History severe hypersensitivity reaction core study History adverse event ( ) ( include core study ) prior start study drug extension study , judgment investigator , take account subject 's overall status , prevent subject enter extension study Clinically significant abnormal liver function test Any medical condition laboratory finding , opinion investigator may interfere participation study , might confound result study , pose additional safety risk administer BYM338</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>sporadic inclusion body myositis ,</keyword>
	<keyword>muscle wasting ,</keyword>
	<keyword>extension study ,</keyword>
	<keyword>BYM338 ,</keyword>
	<keyword>bimagrumab ,</keyword>
</DOC>